Nonalcoholic fatty liver disease

Audience: Patients and providers
Status: Clinical guide · patient + provider
Last updated: 2026-03-27

1. Clinical overview

Nonalcoholic fatty liver disease, now often discussed within MASLD terminology, is excess hepatic fat linked to metabolic dysfunction and should be approached through fibrosis risk, not liver enzymes alone.

2. Common causes and risk factors

Obesity, type 2 diabetes, insulin resistance, dyslipidemia, and metabolic syndrome are core drivers.
OSA, PCOS, and cardiometabolic disease increase progression risk.

3. Typical symptoms

Many patients are asymptomatic; some report fatigue or vague right upper quadrant discomfort.

4. Diagnosis and evaluation

Confirm fatty liver context and exclude other major causes of liver disease when indicated.
Risk-stratify for fibrosis with guideline-based scoring tools and referral thresholds.
Review alcohol exposure, medication causes, diabetes control, weight history, and sleep apnea risk.

5. Treatment (non-pharmacologic)

Sustained weight reduction is the highest-yield intervention.
Improve nutrition quality, physical activity, sleep, and alcohol moderation.
Management should align with broader cardiometabolic risk reduction, not liver findings in isolation.

6. Treatment (pharmacologic)

No single medication is universal, but GLP-1 receptor agonists such as semaglutide or tirzepatide may help when obesity or diabetes is a major driver.
Pioglitazone may be considered in selected patients with diabetes-associated disease under clinician supervision.
Statins, metformin, SGLT2 inhibitors, and other cardiometabolic medications should still be used when indicated even though they are not stand-alone NAFLD cures.

7. Monitoring and follow-up

Track liver enzymes, fibrosis risk scores, weight, A1C, lipids, and blood pressure over time.
Stable enzymes do not rule out clinically important fibrosis progression.

8. Practical counseling points

Explain that fatty liver is a metabolic risk marker, not just a lab abnormality.
Use realistic weight-loss goals and repeat follow-up rather than one-time counseling.
Reinforce avoidance of unproven supplements marketed as liver cures.

9. Red flags and escalation

Escalate for evidence of advanced fibrosis, portal hypertension, jaundice, or synthetic dysfunction.
Refer to hepatology when fibrosis risk is high, diagnosis is uncertain, or liver tests remain unexplained.

10. Guideline references

AASLD NAFLD/MASLD guidance.
EASL and international liver society recommendations.
ADA and obesity-related cardiometabolic guidance where relevant.

Note: Educational guide only; not a substitute for individualized medical care.